Alogliptin: a new addition to the class of DPP-4 inhibitors

References

• DeFronzoRAPathogenesis of type 2 diabetes mellitusMed Clin North Am200488478783515308380
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
   PubMed Web of Science ®Google Scholar
• UK prospective Diabetes Study (UKPDS) GroupIntensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• SaydahSFradkinJCowieCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetesJAMA200429133354214734596
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJBiology of incretins: GLP-1 and GIPGastroenterology200713262131215717498508
   PubMed Web of Science ®Google Scholar
• GautierJFFetitaSSobngwiESalaün-MartinCBiological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetesDiabetes Metab2005313 Pt 12334216142014
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab20063315316516517403
   PubMed Web of Science ®Google Scholar
• YipRGWolfeMMGIP biology and fat metabolismLife Sci20006629110310666005
   PubMed Web of Science ®Google Scholar
• TrümperATrümperKHörschDMechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1) cellsJ Endocrinol2002174223324612176662
   PubMed Web of Science ®Google Scholar
• TrümperATrümperKTrusheimHArnoldRGökeBHörschDGlucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signalingMol Endocrinol20011591559157011518806
   PubMed Web of Science ®Google Scholar
• RossSABrownJCDupréJHypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitusDiabetes1977266525529324834
   PubMed Web of Science ®Google Scholar
• VilsbøllTKrarupTDeaconCFMadsbadSHolstJJReduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patientsDiabetes200150360961311246881
   PubMed Web of Science ®Google Scholar
• LynnFCPamirNNgEHMcIntoshCHKiefferTJPedersonRADefective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker ratsDiabetes20015051004101111334402
   PubMed Web of Science ®Google Scholar
• ZhouJLivakMFBernierMUbiquitination is involved in glucose-mediated downregulation of GIP receptors in isletsAm J Physiol Endocrinol Metab20072932E53854717505054
   PubMed Web of Science ®Google Scholar
• PratleyRIslet dysfunction: An underlying defect in the pathophysiology of type 2 diabetesEndocrinol Metab Clin North Am200635Suppl 161117424674
   PubMed Web of Science ®Google Scholar
• KimWEganJMThe role of incretins in glucose homeostasis and diabetes treatmentPharmacol Rev200860447051219074620
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab20018683717372311502801
   PubMed Web of Science ®Google Scholar
• NauckMStöckmannFEbertRCreutzfeldtWReduced incretin effect in type 2 (non-insulin-dependent) diabetesDiabetologia198629146523514343
   PubMed Web of Science ®Google Scholar
• VollmerKGardiwalHMengeBAHyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humansJ Clin Endocrinol Metab20099441379138519174495
   PubMed Web of Science ®Google Scholar
• VollmerKHolstJJBallerBEllrichmannMNauckMASchmidtWEMeierJJPredictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose toleranceDiabetes200857367868718057091
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtWPreserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusJ Clin Invest19939113013078423228
   PubMed Web of Science ®Google Scholar
• LittleTJPilichiewiczANRussoAEffects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responsesJ Clin Endocrinol Metab20069151916192316492694
   PubMed Web of Science ®Google Scholar
• DupreJGlycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humansRegul Pept2005128214915715780434
   PubMedGoogle Scholar
• ZanderMChristiansenAMadsbadSHolstJJAdditive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetesDiabetes Care20042781910191415277416
   PubMed Web of Science ®Google Scholar
• DegnKBJuhlCBSturisJOne week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetesDiabetes20045351187119415111485
   PubMed Web of Science ®Google Scholar
• MeneillyGSGreigNTildesleyHHabenerJFEganJMElahiDEffects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetesDiabetes Care200326102835284114514588
   PubMed Web of Science ®Google Scholar
• NyströmTGutniakMKZhangQEffects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAm J Physiol Endocrinol Metab20042876E1209121515353407
   PubMed Web of Science ®Google Scholar
• FinemanMSBicsakTAShenLZEffect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesDiabetes Care20032682370237712882864
   PubMed Web of Science ®Google Scholar
• MorettoTMiltonDRidgeTEfficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20083081448146018803987
   PubMed Web of Science ®Google Scholar
• ZinmanBHoogwerfBDurán GarcíaSThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2007146747748517404349
   PubMed Web of Science ®Google Scholar
• DeFronzoRRatnerRHanJKimDFinemanMBaronAEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care20052851092110015855572
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADExenatide-113 Clinical Study GroupEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care200427112628263515504997
   PubMed Web of Science ®Google Scholar
• DupréJBehmeMTMcDonaldTJExendin-4 normalized postcibal glycemic excursions in type 1 diabetesJ Clin Endocrinol Metab20048973469347315240633
   PubMed Web of Science ®Google Scholar
• AhrénBSchmitzOGLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetesHorm Metab Res20043611–1286787615655721
   PubMed Web of Science ®Google Scholar
• MestHJMentleinRDipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetesDiabetologia200548461662015770466
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKASitagliptinDrugs200767458759717352516
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLCariaCWilliams-HermanDKhatamiHSitagliptin Study 023 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia200649112564257117001471
   PubMed Web of Science ®Google Scholar
• ZerilliTPyonEYSitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitusClin Ther200729122614263418201579
   PubMed Web of Science ®Google Scholar
• Williams-HermanDJohnsonJTengREfficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week studyCurr Med Res Opin200925356958319232032
   PubMed Web of Science ®Google Scholar
• RazIChenYWuMEfficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurr Med Res Opin200824253755018194595
   PubMed Web of Science ®Google Scholar
• ScottRLoeysTDaviesMJEngelSSSitagliptin Study 801 GroupEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab2008101095996918201203
   PubMed Web of Science ®Google Scholar
• KarasikAAschnerPKatzeffHDaviesMJSteinPPSitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurr Med Res Opin200824248949618182122
   PubMed Web of Science ®Google Scholar
• CroxtallJDKeamSJVildagliptin: a review of its use in the management of type 2 diabetes mellitusDrugs200868162387240918973400
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res200739321822317373638
   PubMed Web of Science ®Google Scholar
• BosiEDottaFJiaYGoodmanMVildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitusDiabetes Obes Metab2009 Mar 23 Epub ahead of print
   Web of Science ®Google Scholar
• GökeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metforminHorm Metab Res2008401289289518726829
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab200911215716619125777
   PubMed Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin200824102943295218786299
   PubMed Web of Science ®Google Scholar
• MadsbadSKrarupTDeaconCFHolstJJGlucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trialsCurr Opin Clin Nutr Metab Care200811449149918542012
   PubMed Web of Science ®Google Scholar
• FengJZhangZWallaceMBDiscovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IVJ Med Chem2007502297230017441705
   PubMed Web of Science ®Google Scholar
• ChristopherRDavenportMGwaltneySPharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys [abstract]Diabetes200655Suppl 1A107A108
   Google Scholar
• KarimABridsonWFleckPDisposition of the dipeptidyl peptidase-4 inhibitor[14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects [abstract]AAPS J20079S2T3552
   Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase–4 inhibitor alogliptin in healthy male subjectsClin Ther200830351352718405789
   PubMed Web of Science ®Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase–4 inhibitor alogliptin: A randomized, double- blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClin Ther200830349951218405788
   PubMed Web of Science ®Google Scholar
• CovingtonPChristopherRDavenportMLack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects [abstract]Diabetes200756suppl 1A541A542
   PubMed Web of Science ®Google Scholar
• FleckPKarimAHarrisSLack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects [abstract]Diabetes200756suppl 1A?
   Google Scholar
• KarimAFleckPJosephMNo pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride [abstract]Diabetes200756Suppl 1A536
   Google Scholar
• KarimAHarrisSFleckPMoore SchusterJZhangWMekkiQEffect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract 105]J Clin Pharmacol20074791207
   Web of Science ®Google Scholar
• KarimAHarrisSFleckPMooreRZhangWMekkiQAssessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state [abstract 106]J Clin Pharmacol20074791207
   Web of Science ®Google Scholar
• KarimAChiselkoPFleckPHarrisSMunsakaMMekkiQLack of effect of cyclosporine on the single dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects [abstract]Clin Pharmacol Ther200883Suppl 1S13
   Google Scholar
• KarimACopaAFleckPHellandJMunsakaMMekkiQEffects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (ORTHO- NOVUM(R) 1/35) in healthy adult female subjects [abstract]Clin Pharmacol Ther200883SupplS13
   Google Scholar
• KarimAFleckPHarrisSMunsakaMWeissMMekkiQLack of pharmacokinetic interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract]Clin Pharmacol Ther200883Suppl 1S14
   PubMed Web of Science ®Google Scholar
• KarimAFleckPHarrisSWeissMZhangWMekkiQLack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract]Clin Pharmacol Ther200883Suppl 1S12S13
   Google Scholar
• DefronzoRFleckPWilsonCMekkiQAlogliptin Study 010 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care2008312315231718809631
   PubMed Web of Science ®Google Scholar
• PratleyRKipnesMFleckPWilsonCMekkiQAlogliptin Study 007 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapyDiabetes Obes Metab200911216717619125778
   PubMed Web of Science ®Google Scholar
• NauckMEllisGFleckPWilsonCMekkiQAlogliptin Study 008 GroupEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInt J Clin Pract2009631465519125992
   PubMed Web of Science ®Google Scholar
• PratleyRReuschJFleckPWilsonCMekkiQAlogliptin added to pioglitazone therapy improves glycemic control in patients with type 2 diabetes without increasing weight gain or hypoglycemia [abstract]Diabetologia200851Suppl 1S343
   Google Scholar
• RendellMRosenstockJGrossJFleckPWilsonCMekkiQAddition of Alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycemia in patients with type 2 diabetes [abstract]Diabetologia200851Suppl 1S37
   Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKLerchCEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesVasc Health Risk Manag20084475376819065993
   PubMedGoogle Scholar
• RosenstockJSankohSListJFGlucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetesDiabetes Obes Metab200810537638618355324
   PubMed Web of Science ®Google Scholar
• DefronzoRAHissaMNGarberAJfor the Saxagliptin 014 Study GroupThe Efficacy and safety of Saxagliptin when added to Metformin therapy in patients with inadequately controlled Type 2 diabetes on Metformin aloneDiabetes Care2009 Jun 23 Epub ahead of print
   Web of Science ®Google Scholar
• Emea.europa.edu [homepage on the internet]Summary of product characteristics of vildagliptin http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-PI-en.pdfAccessed June 26, 2009
   Google Scholar
• Merck shares Januvia safety data following FDA decision to delay approval of rival drugInternal medicine world reportDecember 2006 http://www.imwr.com/issues/articles/2006-12_45.aspAccessed June 26, 2009
   Google Scholar
• Emea.europa.edu [homepage on the internet]Scientific discussion on vildagliptin: pharmacodynamics, pharmacokinetics, efficacy and safety www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H-807-en6.pdfAccessed June 26, 2009
   Google Scholar
• Fda.gov/medwatch[homepage on the internet]Patient information Januvia102007 www.fda.gov/medwatch/safety/2007/Oct_PI/Januvia_PI.pdfAccessed June 26, 2009
   Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• LambeirAMScharpéSDe MeesterIDPP4 inhibitors for diabetes – what next?Biochem Pharmacol200876121637164318755155
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care200730221722317259484
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab2008101829018034842
   PubMed Web of Science ®Google Scholar
• ReinholdDGoihlAWrengerSRole of dipeptidyl peptidase IV (DPP IV)-like enzymes in T lymphocyte activation: investigations in DPP IV/CD26-knockout miceClin Chem Lab Med2009 Feb 10 Epub ahead of print
   Web of Science ®Google Scholar
• BurkeyBFHoffmannPKHassiepenUTrappeJJuedesMFoleyJEAdverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisitedDiabetes Obes Metab200810111057106118422675
   PubMed Web of Science ®Google Scholar
• KarimAfleckPHetmanLMarburyTRavisWCannonCSingle dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [poster 538 P]Diabetes200857Suppl 1A160
   Google Scholar
• KarimAfleckPDorseyDZhangWMekkiQPrestonRASingle dose pharmacokinetics of alogliptin benzoate(SYR-322) in subjects with moderate hepatic impairment [abstract 107]J Clin Pharmacol20074791207
   Web of Science ®Google Scholar
• NathanDMFinding new treatments for diabetes – how many, how fast... how good?N Engl J Med2007356543744017267901
   PubMed Web of Science ®Google Scholar
• LambeirAMDurinxCScharpéSDe MeesterIDipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IVCrit Rev Clin Lab Sci200340320929412892317
   PubMed Web of Science ®Google Scholar
• ChiaCWEganJMIncretin-based therapies in type 2 diabetes mellitusJ Clin Endocrinol Metab200893103703371618628530
   PubMed Web of Science ®Google Scholar